Evidence map›Paper›PMID 34277519›Full record

ArticleFrontiers in pediatrics2021

Management and Clinical Outcome of Posterior Reversible Encephalopathy Syndrome in Pediatric Oncologic/Hematologic Diseases: A PRES Subgroup Analysis With a Large Sample Size.

Marady Hun, Min Xie, Zhou She, Amin S Abdirahman, Cuifang Li, Feifeng Wu, Senlin Luo, Phanna Han, Rithea Phorn, Pan Wu and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pediatrics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Marady HunDivision of Hematology and Tumor, Children's Medical Center, The Second Xiangya Hospital, Central South University, Changsha, China.
Min XieDivision of Hematology and Tumor, Children's Medical Center, The Second Xiangya Hospital, Central South University, Changsha, China.
Zhou SheDivision of Hematology and Tumor, Children's Medical Center, The Second Xiangya Hospital, Central South University, Changsha, China.
Amin S AbdirahmanDivision of Hematology and Tumor, Children's Medical Center, The Second Xiangya Hospital, Central South University, Changsha, China.
Cuifang LiDivision of Hematology and Tumor, Children's Medical Center, The Second Xiangya Hospital, Central South University, Changsha, China.
Feifeng WuDivision of Hematology and Tumor, Children's Medical Center, The Second Xiangya Hospital, Central South University, Changsha, China.
Senlin LuoDivision of Hematology and Tumor, Children's Medical Center, The Second Xiangya Hospital, Central South University, Changsha, China.
Phanna HanDepartment of Ophthalmology, The Second Xiangya Hospital, Central South University, Changsha, China.
Rithea PhornDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
Pan WuDepartment of Hematology, Hunan Children's Hospital, University of South China, Changsha, China.
Haiyan LuoDepartment of Hematology, Hunan Children's Hospital, University of South China, Changsha, China.
Keke ChenDepartment of Hematology, Children's Medical Center, Hunan Provincial People's Hospital, Hunan Normal University, Changsha, China.
Jidong TianDivision of Hematology and Tumor, Children's Medical Center, The Second Xiangya Hospital, Central South University, Changsha, China.
Wuqing WanDivision of Hematology and Tumor, Children's Medical Center, The Second Xiangya Hospital, Central South University, Changsha, China.
Chuan WenDivision of Hematology and Tumor, Children's Medical Center, The Second Xiangya Hospital, Central South University, Changsha, China.
Second Xiangya Hospital of Central South University · CNCentral South University · CNHunan Children's Hospital · CNHunan Provincial People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study investigated the management and clinical outcomes along with associated factors of posterior reversible encephalopathy syndrome (PRES) in childhood hematologic/oncologic diseases. We present data from children with hematologic/oncologic diseases who developed PRES after treatment of the primary disease with chemotherapy and hematopoietic stem cell transplantation (HSCT) at 3 medical centers in Changsha, China from 2015 to 2020, and review all previously reported cases with the aim of determining whether this neurologic manifestation affects the disease prognosis. In the clinical cohort of 58 PRES patients, hypertension [pooled odds ratio (OR) = 4.941, 95% confidence interval (CI): 1.390, 17.570;

Indexed as

chemotherapychildrenhematopoietic stem cell transplantationmanagementneurotoxicityoncologic/hematologic diseasesposterior reversible encephalopathy syndrome

Identifiers

PMID34277519
PMCPMC8280768
OpenAlexW3184900829

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.